{
    "clinical_study": {
        "@rank": "102620", 
        "acronym": "PROFIL", 
        "arm_group": [
            {
                "arm_group_label": "Sildenafil 80 mg", 
                "arm_group_type": "Experimental", 
                "description": "Sildenafil 80 mg"
            }, 
            {
                "arm_group_label": "Sildenafil 40 mg", 
                "arm_group_type": "Experimental", 
                "description": "Sildenafil 40 mg"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether \"on-demand\" sildenafil is effective in the\n      treatment of Raynaud's phenomenon."
        }, 
        "brief_title": "\"As Required\" Oral Sildenafil in Raynaud's Phenomenon", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Raynaud's Phenomenon", 
        "condition_browse": {
            "mesh_term": "Raynaud Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Active Raynaud's Phenomenon characterized by a clinical history of primary or\n             secondary Raynaud's Phenomenon\n\n          -  At least 7 RP attacks per week on 5 or more days per week (assessed over the 2 weeks\n             preceding inclusion)\n\n          -  Patients who have dated and signed the informed consent form\n\n          -  Contraception for women\n\n        Exclusion Criteria:\n\n          -  Recently diagnosed RP (less than 2 months).\n\n          -  Uncontrolled hypertension, diabetes mellitus, angina\n\n          -  Haemodynamic instability\n\n          -  Nonarteritic ischemic optic neuropathy\n\n          -  Pulmonary hypertension\n\n          -  Subjects currently taking sildenafil, tadalafil or vardenafil\n\n          -  Subjects currently taking nitrates\n\n          -  Subjects currently taking strong CYP3A inhibitors\n\n          -  Pregnancy (or considering pregnancy in the next 4 months)\n\n          -  Breast feeding\n\n          -  Participation in another clinical trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02050360", 
            "org_study_id": "DCIC/12/26", 
            "secondary_id": [
                "2013-000014-38", 
                "12G01"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Sildenafil 40 mg", 
                "intervention_name": "Sildenafil 40 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sildenafil 80 mg", 
                "intervention_name": "Sildenafil 80 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sildenafil"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Raynaud's phenomenon", 
            "Sildenafil", 
            "Systemic Sclerosis", 
            "Local cooling", 
            "Microcirculation"
        ], 
        "lastchanged_date": "January 29, 2014", 
        "location": {
            "contact": {
                "email": "JLCracowski@chu-grenoble.fr", 
                "last_name": "Jean-Luc CRACOWSKI, MD, PhD"
            }, 
            "contact_backup": {
                "email": "MRoustit@chu-grenoble.fr", 
                "last_name": "Matthieu ROUSTIT, PhamD- PhD"
            }, 
            "facility": {
                "address": {
                    "city": "Grenoble", 
                    "country": "France"
                }, 
                "name": "Clinical Investigation Center - Pharmacology Unit - University Hospital of Grenoble"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "3", 
        "official_title": "Efficacy and Safety of \"as Required\" Sildenafil for Patients With Moderate to Severe Raynaud's Phenomenon (RP)", 
        "overall_contact": {
            "email": "MRoustit@chu-grenoble.fr", 
            "last_name": "Matthieu Roustit, PharmD, PhD"
        }, 
        "overall_official": {
            "affiliation": "INSERM CIC03 - Unit\u00e9 de Pharmacologie Clinique", 
            "last_name": "Jean-Luc CRACOWSKI, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "RCS is self-reported every day and averaged over 7-day periods", 
            "measure": "Mean change in the Raynaud's Condition Score (RCS) during treatment, as compared to placebo.", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02050360"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "An attack is defined as an episode of pallor or cyanosis (with or without pain,tingling or numbness). The number of attacks is self-reported every day and averaged over 7-day periods", 
                "measure": "Frequency of RP: number of RP attacks during treatment, as compared to placebo.", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "measure": "Patients' preference: comparison between the number of patients favoring a treatment to another.", 
                "safety_issue": "No", 
                "time_frame": "Every 3 weeks of treatment (week 3, 6 and 9)"
            }, 
            {
                "description": "Pain  associated with each attack is self-reported on a 10-point scale, and averaged over 7-day periods", 
                "measure": "Pain associated with RP: Mean change in the Raynaud's pain score during treatment, as compared to placebo.", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "measure": "Frequency and severity of adverse drug events during treatment, as compared to placebo", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }, 
            {
                "measure": "Microvascular reactivity: index of skin perfusion in response to local/regional cooling after a single dose of sildenafil, as compared to placebo (laboratory experiments)", 
                "safety_issue": "No", 
                "time_frame": "Week 1, 2 and 3"
            }
        ], 
        "source": "University Hospital, Grenoble", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Grenoble", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}